A central point in the profile of Gemcitabine is the relationship between its molecular action and the cancer setting in which it is used. Inhibits DNA synthesis through active metabolites and causes masked-chain termination and ribonucleotide depletion. The drug interferes with nucleotide metabolism or related cellular pathways, limiting the ability of actively dividing tumor cells to synthesize or process essential DNA building blocks. The record identifies it as Pyrimidine nucleoside analog within Chemotherapy; Antimetabolite and lists Pancreatic; Biliary Tract; Bladder; Breast; NSCLC; Ovarian among the associated tumor types. The principal indications are Pancreatic, biliary tract, bladder, ovarian, breast, NSCLC and other solid tumors. Regimen examples include GemCis/CisGem; gemcitabine + nab-paclitaxel; gemcitabine + carboplatin; gemcitabine + docetaxel. The combination context matters: depending on the disease, the agent may be used alone or alongside other systemic treatments as specified in the database. Its clinical role is defined by the disease-specific regimen, treatment intent, and patient-selection criteria associated with the listed indications. Any biomarker or disease-state requirement included in the indication should be considered when interpreting the entry. The same broad therapeutic class can contain medicines with different targets and therefore different clinical uses. Current labels and applicable oncology guidelines should be consulted to confirm present-day indications and combinations.